Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective

Biochemistry

Volumn 46, Issue 22, 2007, Pages 6607-6616

  Renedo, Marta ^a   Gayarre, Javier ^a   García Domínguez, Carlota A ^b   Pérez Rodríguez, Andrea ^b   Prieto, Alicia ^a   Javier Canada F ^a   Rojas, José M ^b   Pérez Sala, Dolores ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTENONE PROSTANOIDS (CYP); ELECTROPHILIC PROSTANOIDS; PROTEIN MOLECULES; THERAPEUTIC AGENTS;

ADDITION REACTIONS; CELLS; CHEMICAL ACTIVATION; CHEMICAL MODIFICATION; DRUG PRODUCTS; MOLECULAR INTERACTIONS; MOLECULAR STRUCTURE;

PROTEINS;

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 8 ISOPROSTAGLANDIN A1; CYCLOPENTENONE DERIVATIVE; DELTA12 PROSTAGLANDIN J2; GLUTATHIONE; PROSTAGLANDIN A1; PROSTANOID; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICHAEL ADDITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN STRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CYSTEINE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICE; PROSTAGLANDIN D2; PROSTAGLANDINS; PROSTAGLANDINS A; PROTEIN BINDING; RAS PROTEINS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 34249893910     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi602389p     Document Type: Article

References (52)

1. Musiek, E. S., Breeding, R. S., Milne, G. L., Zanoni, G., Morrow, J. D., and McLaughlin, B. (2006) Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration, J. Neurochem. 97, 1301-1313.
2. Straus, D. S., and Glass, C. K. (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets, Med. Res. Rev. 21, 185-210.
3. Roberts, L. J., II, and Morrow, J. D. (2002) Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation, Cell. Mol. Life Sci. 59, 808-820.
4. Noyori, R., and Suzuki, M. (1993) Organic synthesis of prostaglandins: advancing biology, Science 259, 44-45.
5. Zanoni, G., Porta, A., Castronovo, F., and Vidari, G. (2003) First total synthesis of JS isoprostane, J. Org. Chem. 68, 6005-6010.
6. 1 methyl esters with thiols, J. Am. Chem. Soc. 119, 2376-2385.
7. Stamatakis, K., Sánchez-Gómez, F. J., and Pérez-Sala, D. (2004) Protein modification by cyclopentenone prostaglandin addition: biological actions and therapeutic implications, Gene Ther. Mol. Biol. 8, 241-258.
8. Musiek, E. S., Milne, G. L., McLaughlin, B., and Morrow, J. D. (2005) Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity, Brain Pathol. 15, 149-158.
9. Levonen, A. L., Dickinson, D. A., Moellering, D. R., Mulcahy, R. T., Forman, H. J., and Darley-Usmar, V. M. (2001) Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells, Arterioscler., Thromb., Vasc. Biol. 21, 1846-1851.
10. Zhang, H. L., Huang, Z. H., Zhu, Y., Liang, Z. Q., Han, R., Wang, X. X., Chase, T. N., and Qin, Z. H. (2005) Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia, Brain Res. 1039, 203-206.
11. Dugo, L., Collin, M., Cuzzocrea, S., and Thiemermann, C. (2004) 15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria, Eur. J. Pharmacol. 498, 295-301.
12. Ianaro, A., Ialenti, A., Maffia, P., Di Meglio, P., Di Rosa, M., and Santoro, M. G. (2003) Anti-inflammatory activity of 15-deoxy-delta12,14-PGJ2 and 2-cyclopenten-1-one: role of the heat shock response, Mol. Pharmacol. 64, 85-93.
13. Kim, I. K., Lee, J. H., Sohn, H. W., Kim, H. S., and Kim, S. H. (1993) Prostaglandin A2 and delta 12-prostaglandin J2 induce apoptosis in L1210 cells, FEBS Lett. 321, 209-214.
14. Tanikawa, M., Yamada, K., Tominaga, K., Morisaki, H., Kaneko, Y., Ikeda, K., Suzuki, M., Kiho, T., Tomokiyo, K., Furuta, K., Noyori, R., and Nakanishi, M. (1998) Potent prostaglandin A1 analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E, J. Biol. Chem. 273, 18522-18527.
15. 2 in mesangial cells reveals multiple interactions with the cytoskeleton, J. Am. Soc. Nephrol. 17, 89-98.
16. Landar, A., Shiva, S., Levonen, A. L., Oh, J. Y., Zaragoza, C., Johnson, M. S., and Darley-Usmar, V. M. (2006) Induction of the permeability transition and cytochrome c release by 15-deoxy prostaglandin J2 in mitochondria, Biochem. J. 394, 185-195.
17. Kato, T., Fukushima, M., Kurozumi, S., and Noyori, R. (1986) Antitumor activity of delta 7-prostaglandin A1 and delta 12-prostaglandin J2 in vitro and in vivo, Cancer Res. 46, 3538-3542.
18. Suzuki, M., Kiho, T., Tomokiyo, K., Furuta, K., Fukushima, S., Takeuchi, Y., Nakanishi, M., and Noyori, R. (1998) Rational design of antitumor prostaglandins with high biological stability, J. Med. Chem. 41, 3084-3090.
19. Bickley, J. F., Ciucci, A., Evans, P., Roberts, S. M., Ross, N., and Santoro, G. M. (2004) Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers, Bioorg. Med. Chem. 12, 3221-3227.
20. Barbacid, M. (1987) ras genes, Annu. Rev. Biochem. 56, 779-827.
21. Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., and Katsuki, M. (1997) K-ras is essential for the development of the mouse embryo, Oncogene 15, 1151-1159.
22. Esteban, L. M., Vicario-Abejon, C., Fernandez-Salguero, P., Fernandez-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., Pellicer, A., and Santos, E. (2001) Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development, Mol. Cell. Biol. 21, 1444-1452.
23. Pérez-Sala, D., Martínez-A., C., and Rebollo, A. (1999) Novel aspects of Ras proteins biology: regulation and implications, Cell Death Differ. 6, 722-728.
24. Choi, J. A., Park, M. T., Kang, C. M., Um, H. D., Bae, S., Lee, K. H., Kim, T. H., Kim, J. H., Cho, C. K., Lee, Y. S., Chung, H. Y., and Lee, S. J. (2004) Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways, Oncogene 23, 9-20.
25. Oliva, J. L., Zarich, N., Martinez, N., Jorge, R., Castrillo, A., Azanedo, M., Garcia-Vargas, S., Gutierrez-Eisman, S., Juarranz, A., Bosca, L., Gutkind, J. S., and Rojas, J. M. (2004) The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras, J. Biol. Chem. 279, 33480-33491.
26. Newman, C. M., and Magee, A. I. (1993) Posttranslational processing of the ras superfamily of small GTP-binding proteins, Biochim. Biophys. Acta 1155, 79-96.
27. Hancock, J. F., Magee, A. I., Childs, J. E., and Marshall, C. J. (1989) All ras proteins are polyisoprenylated but only some are palmitoylated, Cell 57, 1167-1177.
28. Rando, R. R. (1996) Chemical biology of protein isoprenylation/ methylation, Biochim. Biophys. Acta 1300, 5-16.
29. Hancock, J. F., Paterson, H., and Marshall, C. J. (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane, Cell 63, 133-139.
30. Lu, J. Y., and Hofmann, S. L. (1995) Depalmitoylation of CAAX motif proteins. Protein structural determinants of palmitate turnover rate, J. Biol. Chem. 270, 7251-7256.
31. Rocks, O., Peyker, A., Kahms, M., Verveer, P. J., Koerner, C., Lumbierres, M., Kuhlmann, J., Waldmann, H., Wittinghofer, A., and Bastiaens, P. I. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms, Science 307, 1746-1752.
32. 2 binds to and activates H-Ras, Proc. Natl. Acad. Sci. U.S.A. 100, 4772-4777.
33. 2 in a model of skin carcinogenesis, Carcinogenesis 27, 328-336.
34. 2, J. Biol. Chem. 278, 51251-51260.
35. Zarich, N., Oliva, J. L., Jorge, R., Santos, E., and Rojas, J. M. (2000) The isoform-specific stretch of hSos1 defines a new Grb2-binding domain, Oncogene 19, 5872-5883.
36. Heo, J., Prutzman, K. C., Mocanu, V., and Campbell, S. L. (2005) Mechanism of free radical nitric oxide-mediated Ras guanine nucleotide dissociation, J. Mol. Biol. 346, 1423-1440.
37. 2: role of glutathione, FEBS Lett. 579, 5803-5808.
38. 2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes, Mol. Pharmacol. 66, 1349-1358.
39. 2 inhibition of NF-κB DNA binding through covalent modification of the p50 subunit, J. Biol. Chem. 276, 35530-35536.
40. Shibata, T., Yamada, T., Ishii, T., Kumazawa, S., Nakamura, H., Masutani, H., Yodoi, J., and Uchida, K. (2003) Thioredoxin as a molecular target of cyclopentenone prostaglandins, J. Biol. Chem. 278, 26046-26054.
41. Levonen, A. L., Landar, A., Ramachandran, A., Ceaser, E. K., Dickinson, D. A., Zanoni, G., Morrow, J. D., and Darley-Usmar, V. M. (2004) Cellular mechanisms of redox cell signaling: the role of cysteine modification in controlling antioxidant defenses in response to electrophilic lipid oxidation products, Biochem. J. 378, 373-382.
42. Wagner, T. M., Mullally, J. E., and Fitzpatrick, F. A. (2006) Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1 / STK11: Cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation, J. Biol. Chem. 281, 2598-2604.
43. 2, Biochemistry 29, 3760-3765.
44. Mallis, R. J., Buss, J. E., and Thomas, J. A. (2001) Oxidative modification of H-ras: S-thiolation and S-nitrosylation of reactive cysteines, Biochem. J. 355, 145-153.
45. Lander, H. M., Hajjar, D. P., Hempstead, B. L., Mirza, U. A., Chait, B. T., Campbell, S., and Quilliam, L. A. (1997) A molecular redox switch on p21ras. Structural basis for the nitric oxide-p21ras interaction, J. Biol. Chem. 272, 4323-4326.
46. Heo, J., and Campbell, S. L. (2005) Superoxide anion radical modulates the activity of Ras and Ras-related GTPases by a radical-based mechanism similar to that of nitric oxide, J. Biol. Chem. 280, 12438-12445.
47. Mott, H. R., Carpenter, J. W., and Campbell, S. L. (1997) Structural and functional analysis of a mutant Ras protein that is insensitive to nitric oxide activation, Biochemistry 36, 3640-3644.
48. Roy, S., Plowman, S., Rotblat, B., Prior, I. A., Muncke, C., Grainger, S., Parton, R. G., Henis, Y. I., Kloog, Y., and Hancock, J. F. (2005) Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling, Mol. Cell. Biol. 25, 6722-6733.
49. Baker, T. L., Booden, M. A., and Buss, J. E. (2000) S-Nitrosocysteine increases palmitate turnover on Ha-Ras in NIH 3T3 cells, J. Biol. Chem. 275, 22037-22047.
50. Pignatelli, M., Sanchez-Rodriguez, J., Santos, A., and Perez-Castillo, A. (2005) 15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism, Carcinogenesis 26, 81-92.
51. Paz, A., Haklai, R., Elad, G., Ballan, E., and Kloog, Y. (2000) Galectin-1 binds H-ras to mediate Ras membrane anchorage and cell transformation, Oncogene 20, 7486-7493.
52. Prior, I. A., Harding, A., Yan, J., Sluimer, J., Parton, R. G., and Hancock, J. F. (2001) GTP-dependent segregation of H-ras from lipid rafts is required for biological activity, Nat. Cell Biol. 3, 368-375.